Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal for Healthcare Quality : Official Publication of the National Association for Healthcare Quality|August 9, 2014
Measuring Hospital-Wide Mortality-Pitfalls and PotentialSimon J Mackenzie, Don A Goldmann, Rocco J Perla, et al.
Bioorganic & Medicinal Chemistry Letters|February 29, 2008
Rhodanine derivatives as novel inhibitors of PDE4Mark W Irvine, Graham L Patrick, Justin Kewney, et al.
Critical Care (London, England)|April 17, 2013
Mortality and quality of life in the five years after severe sepsisBrian H Cuthbertson, Andrew Elders, Sally Hall, et al.
Respiratory Research|June 1, 2004
The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthmaRobert A Clayton, Colin A J Dick, Alison Mackenzie, et al.
British Journal of Pharmacology|May 25, 2002
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)Simon J MacKenzie, George S Baillie, Ian McPhee, et al.
European Journal of Pharmacology|May 6, 2006
The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme familyLucien C D Gibson, Stuart F Hastings, Ian McPhee, et al.
Trials|January 31, 2014
A rehabilitation intervention to promote physical recovery following intensive care: a detailed description of construct development, rationale and content together with proposed taxonomy to capture processes in a randomised controlled trialPam Ramsay, Lisa G Salisbury, Judith L Merriweather, et al.
BMJ Open|July 5, 2012
A randomised controlled trial evaluating a rehabilitation complex intervention for patients following intensive care discharge: the RECOVER studyTimothy Simon Walsh, Lisa G Salisbury, Julia Boyd, et al.
American Journal of Respiratory and Critical Care Medicine|March 28, 2009
C5a mediates peripheral blood neutrophil dysfunction in critically ill patientsAndrew Conway Morris, Kallirroi Kefala, Thomas S Wilkinson, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2007
2-Aryl-3,3,3-trifluoro-2-hydroxypropionic acids: a new class of protein tyrosine phosphatase 1B inhibitorsDavid R Adams, Achamma Abraham, Jun Asano, et al.
Pageof 2